Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

EBMT 2024 | Optimizing haplo-SCT for the treatment of AML

Arnon Nagler • 16 Apr 2024
EBMT 2024
Acute Myeloid Leukemia Leukemia Cyclophosphamide

Arnon Nagler, MD, Chaim Sheba Medical Center, Tel-Aviv, Israel, discusses advancements in haploidentical stem cell transplantation (haplo-SCT) for the treatment of acute myeloid leukemia (AML). He discusses the use of post-transplant cyclophosphamide (PTCy) to mitigate graft-versus-host disease (GvHD), with the potential addition of anti-thymocyte globulin (ATG). He also points out the benefits of using non-myeloablative conditioning, especially for older patients. This interview took place at the 50th Annual Meeting of the EBMT in Glasgow, Scotland.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

More from Arnon Nagler

2:42
Factors to consider when using haplo-SCT: donor selection criteria and source of stem cells
Arnon Nagler • 16 Apr 2024
1:21
Trends in alloSCT for good-risk AML: a longitudinal study
Arnon Nagler • 9 Dec 2023
2:15
GvHD prophylaxis post-alloSCT: PTCy versus ATG
Arnon Nagler • 9 Dec 2023
2:13
Haploidentical SCT for the treatment of secondary AML
Arnon Nagler • 9 Dec 2023

Related Videos

8:40
Investigating PP2A-based therapeutic strategies for KMT2A-rearranged acute leukemia
Maria Teresa Esposito • 25 Apr 2024
1:55
Factors to consider when choosing a treatment option for patients with CLL
Piers Patten • 28 Apr 2024
1:17
The curative potential of alloSCT in the treatment of HR-MDS
Jurjen Versluis • 22 Apr 2024
10:34
Remission induction therapy prior to alloSCT in AML: insights from the ASAP trial
Johannes Schetelig • 19 Apr 2024
The content of VJHemOnc is intended for healthcare professionals